N-Glycomic changes in human breast carcinoma MCF-7 and T-Lymphoblastoid cells after treatment with Herceptin and Herceptin/Lipoplex

Download
  1. (PDF, 529 KB)
  2. Get@NRC: N-Glycomic changes in human breast carcinoma MCF-7 and T-Lymphoblastoid cells after treatment with Herceptin and Herceptin/Lipoplex (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1021/pr9010266
AuthorSearch for: ; Search for: ; Search for: ; Search for:
TypeArticle
Journal titleJournal of Proteome Research
Volume9
Issue3
Pages15331540; # of pages: 8
SubjectN-Glycans; MCF-7 cells; breast carcinoma; CEM cells; mass spectrometry
AbstractThe humanized monoclonal antibody IgG1 in combination with chemotherapy has been demonstrated to enhance survival benefit in cancer treatment. Despite positive outcomes, some cancer cells develop multidrug resistance. Numerous mechanisms in cancers can be involved in the process of treatment therapy and most of them are not still well understood. To address how the carbohydrate moieties of cells are affected during treatment, the glycan profiles from the two most common cancer cell lines — human breast MCF-7 carcinoma and T-lymphoblastoid CEM cells — were studied here and compared with profiles after treatment with Herceptin alone or in combination with Lipofectamine mixed with plasmid DNA to form Lipoplex. N-Glycans were released from total cells by digestion with PNGaseF and analyzed by matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS). In summary, both original cell lines showed a dominant occurrence of high-mannose glycans. After treatment, these structures were suppressed and biantennary core-fucosylated glycans originating from IgG1 were the major carbohydrate products identified in cells. The high incidence of additional fucosylated or nonfucosylated galactosylated oligosaccharides, which were not detected in original cells or Herceptin, varied with conditions and time of exposure of cells to the antibody. The results presented in this study provide strong evidence for a role of glycosylation during antibody treatment.
Publication date
LanguageEnglish
AffiliationNRC Institute for Biodiagnostics; National Research Council Canada
Peer reviewedYes
NPARC number17673487
Export citationExport as RIS
Report a correctionReport a correction
Record identifiere431d94f-79ff-4278-836f-02f60e34eee6
Record created2011-04-03
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)